MNPR Monopar Therapeutics Inc.

FDA Catalyst Company
1.9
-0.07  -4%
Previous Close 1.97
Open 2.02
52 Week Low 1.7023
52 Week High 6.98
Market Cap $20,399,152
Shares 10,736,396
Float 4,378,045
Enterprise Value $7,633,323
Volume 3,944
Av. Daily Volume 7,899
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/01/2021
Roth Capital Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 01/28/2021
Maxim Group Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 09/24/2020
Brookline Capital Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 02/19/2020
JonesTrading Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 02/03/2020

Latest News

  1. Validive® Phase 2b/3 VOICE Trial Continues Enrolling Patients Toward Interim
    Camsirubicin Phase 1b Dose-Escalation Trial Clears 3rd Dose Level, Now Enrolling 4th

    WILMETTE, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced first quarter 2022 financial results and summarized recent program developments.

    Recent Program Developments

    Validive – International Phase 2b/3 VOICE Clinical Trial, Actively Recruiting

    • The VOICE trial continues to enroll patients and add additional clinical sites, with the interim analysis…
    View Full Article
  2. Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe

    Camsirubicin Phase 1b Dose-Esclation Trial Clears 2nd Dose Level and is Now Enrolling 3rd Dose-Level Cohort

    WILMETTE, Ill., March 24, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced fourth quarter and full-year 2021 financial results and summarized recent program developments.

    Recent Program Developments and Highlights

    Validive – International Phase 2b/3 VOICE Clinical Trial, Actively Recruiting

    • Validive…
    View Full Article
  3. WILMETTE, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar's Chief Executive Officer, will present at the 34th Annual Roth Conference and Maxim's 2022 Virtual Growth Conference.

    Presentation Details:

    34th Annual Roth Conference

    https://www.roth.com/conferences/upcoming-conferences
    Date: March 14, 2022
    Time: 1:30pm Pacific Time
    Location: The Ritz Carlton, Laguna Niguel located in Dana Point, California

    Maxim's 2022 Virtual Growth Conference

    https://www.m-vest.com/home
    Date: March 30, 2022
    Time…

    View Full Article
    • Validive Phase 2b/3 VOICE trial now open at 43 sites; active and enrolling in US and EU
    • Open-label Phase 1b camsirubicin trial: early signs of clinical benefit observed

    WILMETTE, Ill., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced program updates across its pipeline and anticipated 2022 highlights.

    Program Developments

    Validive – International Phase 2b/3 VOICE Clinical Trial, Actively Recruiting

    Severe oral mucositis (SOM) is a painful and debilitating ulceration of the mucosal membranes of the mouth caused by the chemoradiotherapy…

    View Full Article
  4. WILMETTE, Ill., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar's Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference. The presentation will be available for on-demand viewing starting on Monday, January 10, 2022 at 7:00am ET.

    Presentation Details:

    Date: Monday, January 10, 2022

    Time: 7:00am ET

    Location: Virtual

    https://hcwevents.com/

    About Monopar Therapeutics Inc.

    Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary…

    View Full Article
View All Monopar Therapeutics Inc. News